Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles
暂无分享,去创建一个
Eric Pridgen | Omid C. Farokhzad | Frank Alexis | Linda K. Molnar | O. Farokhzad | F. Alexis | Eric M. Pridgen | Linda Molnar
[1] H. Lijnen. Angiogenesis and obesity. , 2008, Cardiovascular research.
[2] L. Zhang,et al. Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.
[3] Robert Langer,et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers , 2008, Proceedings of the National Academy of Sciences.
[4] Robert Langer,et al. New frontiers in nanotechnology for cancer treatment. , 2008, Urologic oncology.
[5] Sung-Bae Kim,et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer , 2008, Breast Cancer Research and Treatment.
[6] C. van Nostrum,et al. Hydrolysable core-crosslinked thermosensitive polymeric micelles: synthesis, characterisation and in vivo studies. , 2007, Biomaterials.
[7] Dong-Wan Kim,et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] Robert Langer,et al. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. , 2007, Nanomedicine.
[9] J. Homsi,et al. Phase I Trial of Poly-l-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies , 2007, Clinical Cancer Research.
[10] Wolfgang A. Weber,et al. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging , 2007, Proceedings of the National Academy of Sciences.
[11] K. Higaki,et al. Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. , 2007, International journal of pharmaceutics.
[12] Gert Storm,et al. Sheddable Coatings for Long-Circulating Nanoparticles , 2007, Pharmaceutical Research.
[13] Mark E. Davis,et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA , 2007, Proceedings of the National Academy of Sciences.
[14] Mansoor M. Amiji,et al. Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery , 2007, Pharmaceutical Research.
[15] Filip Braet,et al. Contribution of high‐resolution correlative imaging techniques in the study of the liver sieve in three‐dimensions , 2007, Microscopy research and technique.
[16] A. Chetta,et al. Vascular remodelling and angiogenesis in asthma: morphological aspects and pharmacological modulation. , 2007, Inflammation & allergy drug targets.
[17] M. Amiji,et al. Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. , 2007, Journal of pharmaceutical sciences.
[18] Robert Langer,et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. , 2007, Biomaterials.
[19] Christopher G Thanos,et al. Targeted nanoparticle-based drug delivery and diagnosis , 2007, Journal of drug targeting.
[20] Khaled Greish,et al. Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines , 2007, Journal of drug targeting.
[21] S. Gopinath. Methods developed for SELEX , 2006, Analytical and bioanalytical chemistry.
[22] J. Schellens,et al. Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients , 2007, Cancer Chemotherapy and Pharmacology.
[23] A. Domb,et al. PEG-PLA block copolymer as potential drug carrier: preparation and characterization. , 2006, Macromolecular bioscience.
[24] R. Langer,et al. Nanomedicine: developing smarter therapeutic and diagnostic modalities. , 2006, Advanced drug delivery reviews.
[25] S Moein Moghimi,et al. Recent developments in polymeric nanoparticle engineering and their applications in experimental and clinical oncology. , 2006, Anti-cancer agents in medicinal chemistry.
[26] J. Richie,et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[27] J. Rice,et al. Preclinical Efficacy and Pharmacokinetics of AP5346, A Novel Diaminocyclohexane-Platinum Tumor-Targeting Drug Delivery System , 2006, Clinical Cancer Research.
[28] Jianjun Cheng,et al. Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models , 2006, Clinical Cancer Research.
[29] David Schrama,et al. Antibody targeted drugs as cancer therapeutics , 2006, Nature Reviews Drug Discovery.
[30] Nicholas A Peppas,et al. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.
[31] Hong-Zhuan Chen,et al. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[32] Jianjun Cheng,et al. Pharmacokinetics and biodistribution of the camptothecin–polymer conjugate IT-101 in rats and tumor-bearing mice , 2006, Cancer Chemotherapy and Pharmacology.
[33] Catherine Shaffer. Nanomedicine transforms drug delivery. , 2005, Drug discovery today.
[34] R. Langer,et al. Poly(Ethylene Oxide)-Modified Poly(β-Amino Ester) Nanoparticles as a pH-Sensitive System for Tumor-Targeted Delivery of Hydrophobic Drugs: Part 2. In Vivo Distribution and Tumor Localization Studies , 2005, Pharmaceutical Research.
[35] A. Tolcher,et al. Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas , 2005, Clinical Cancer Research.
[36] J. Sludden,et al. A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules , 2005, Clinical Cancer Research.
[37] F. Izzo,et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] Anna M Wu,et al. Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.
[39] J. L. Turner,et al. An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution. , 2005, Biomacromolecules.
[40] K. Avgoustakis,et al. Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers. , 2005, International journal of pharmaceutics.
[41] J. Wanders,et al. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[42] K. Norrby,et al. Increased angiogenesis in diabetes , 1990, Experientia.
[43] S. Jeffers,et al. Pegylated liposomal doxorubicin ( doxil ) : Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg / m 2 , 2005 .
[44] P. Sabbatini,et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] Omid C. Farokhzad,et al. Nanoparticle-Aptamer Bioconjugates , 2004, Cancer Research.
[46] H. Ueno,et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin , 2004, British Journal of Cancer.
[47] K. Avgoustakis,et al. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. , 2004, Current drug delivery.
[48] Nicholas A Peppas,et al. Intelligent therapeutics: biomimetic systems and nanotechnology in drug delivery. , 2004, Advanced Drug Delivery Reviews.
[49] Tae-You Kim,et al. Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies , 2004, Clinical Cancer Research.
[50] D. Kerr,et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer , 2004, British Journal of Cancer.
[51] J. Frank,et al. Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon? , 2004, Journal of the Neurological Sciences.
[52] J. Kreuter,et al. Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles , 1999, Pharmaceutical Research.
[53] A. Hanauske,et al. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD) , 1993, Investigational New Drugs.
[54] W. Stehbens,et al. Vesicles of fenestrated and non-fenestrated endothelium , 1969, Zeitschrift für Zellforschung und Mikroskopische Anatomie.
[55] J. Folkman,et al. Fundamental concepts of the angiogenic process. , 2003, Current molecular medicine.
[56] A. Anagnostopoulos,et al. Safety of high‐dose liposomal daunorubicin (daunoxome) for refractory or relapsed acute myeloblastic leukaemia , 2003, British journal of haematology.
[57] Christilyn P. Graff,et al. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. , 2003, Cancer research.
[58] D. Sane,et al. Abnormal angiogenesis in diabetes mellitus , 2003, Medicinal research reviews.
[59] Kazunori Kataoka,et al. PEGylated Nanoparticles for Biological and Pharmaceutical Applications , 2003 .
[60] Kazunori Kataoka,et al. PEGylated nanoparticles for biological and pharmaceutical applications. , 2003, Advanced drug delivery reviews.
[61] J. Folkman,et al. Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.
[62] J. Bomalaski,et al. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. , 2002, Cancer research.
[63] Y. Teramura,et al. Rolling properties of rGPIBα-conjugated phospholipid vesicles with different membrane flexibilities on vWf surface under flow conditions , 2002 .
[64] O. Bourdon,et al. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. , 2001, Biomaterials.
[65] Y. Sugiyama,et al. Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[66] J. Hopewell,et al. Preclinical evaluation of the cardiotoxicity of PK2: A novel HPMA copolymer–doxorubicin–galactosamine conjugate antitumour agent , 2001, Human & experimental toxicology.
[67] K. Avgoustakis,et al. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. , 2001, International journal of pharmaceutics.
[68] S M Moghimi,et al. Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.
[69] H. S. Oh,et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[70] H. Maeda. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.
[71] Y Li,et al. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[72] J. Schellens,et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel , 2001, Anti-cancer drugs.
[73] J. Kreuter,et al. Nanoparticulate systems for brain delivery of drugs. , 2001, Advanced drug delivery reviews.
[74] Louis M Weiner,et al. New approaches to antibody therapy , 2000, Oncogene.
[75] R. Müller,et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. , 2000, Colloids and surfaces. B, Biointerfaces.
[76] S M Moghimi,et al. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. , 2000, Trends in biotechnology.
[77] S. Groshen,et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[78] C. Charnsangavej,et al. Biodistribution of paclitaxel and poly(l-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor , 2000, Cancer Chemotherapy and Pharmacology.
[79] P Couvreur,et al. Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. , 1999, Biomaterials.
[80] P. Couvreur,et al. Stealth® PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting , 1999 .
[81] L. Murray,et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[82] L. Murray,et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[83] M D Scott,et al. Cellular camouflage: fooling the immune system with polymers. , 1998, Current pharmaceutical design.
[84] R. Jain,et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[85] F. Muggia. Doxil in breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] C. Conover,et al. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker , 1998, Cancer Chemotherapy and Pharmacology.
[87] FDA approves DaunoXome as first-line therapy for Kaposi's sarcoma. Food and Drug Administration. , 1996, Journal of the International Association of Physicians in AIDS Care.
[88] D. Bazile,et al. Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators. , 1996, Biomaterials.
[89] D. Fisher,et al. Polyethylene glycol modification: relevance of improved methodology to tumour targeting. , 1996, Journal of drug targeting.
[90] D. Bazile,et al. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. , 1995, Journal of pharmaceutical sciences.
[91] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[92] V. Torchilin,et al. Biodegradable long-circulating polymeric nanospheres. , 1994, Science.
[93] D Tomlinson,et al. Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS. , 1994, Clinical oncology (Royal College of Radiologists (Great Britain)).
[94] D. Predescu,et al. Plasmalemmal vesicles represent the large pore system of continuous microvascular endothelium. , 1993, The American journal of physiology.
[95] N. Düzguneş. Targeted drug delivery. , 1992, Journal of the California Dental Association.
[96] D. Ingber,et al. Inhibition of angiogenesis. , 1992, Seminars in cancer biology.
[97] R. Eisenstein. Angiogenesis in arteries: review. , 1991, Pharmacology & therapeutics.
[98] J. Scott,et al. Searching for peptide ligands with an epitope library. , 1990, Science.
[99] R. Jain,et al. Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. , 1990, Cancer research.
[100] J. Folkman,et al. What is the role of endothelial cells in angiogenesis? , 1984, Laboratory investigation; a journal of technical methods and pathology.
[101] Brigham Kl. Estimations of permeability properties of pulmonary capillaries (continuous endothelium). , 1980 .
[102] K. Brigham. Estimations of permeability properties of pulmonary capillaries (continuous endothelium). , 1980, The Physiologist.
[103] U. Ryan,et al. Fenestrated endothelium of the adrenal gland: freeze-fracture studies. , 1975, Tissue & cell.
[104] Maia Simionescu,et al. MORPHOMETRIC DATA ON THE ENDOTHELIUM OF BLOOD CAPILLARIES , 1974, The Journal of cell biology.
[105] M. El-Shahawy. Angiogenesis in progressive systemic sclerosis. , 1972 .
[106] R. Siegel. Angiogenesis in progressive systemic sclerosis. , 1972, The New England journal of medicine.
[107] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.